glp 1 price decrease GLP-1s and the Unintended Consequences of the $100 Billion Market Recent Trends in GLP-1 Use
Description
Grassi G, Mark A, Esler M

Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study

South Dakota with $117 million
Its mainly the C10 fat (capric acid) that may boost GLP-1

Endurance athletes have unique nutritional and performance demands, and GLP-1 drugs can significantly alter ones appetite, hydration, and metabolism
